A major breakthrough came in 2017 with the approval of Luxturna, an AAV2-based therapy for biallelic RPE65-associated Leber congenital amaurosis (LCA), marking the first successful clinical translation of AAV in IRDs [53]. This evidence concerns the gene RPE65 and Leber congenital amaurosis.